Filing Details

Accession Number:
0001735276-24-000016
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-29 16:16:50
Reporting Period:
2024-02-27
Accepted Time:
2024-02-29 16:16:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178670 Alnylam Pharmaceuticals Inc. ALNY Pharmaceutical Preparations (2834) 770602661
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1708764 Lall Indrani Franchini 675 West Kendall Street
Henri A. Termeer Square
Cambridge MA 02142
Evp, Clo & Secretary No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-02-27 878 $0.00 4,462 No 4 M Direct
Common Stock Disposition 2024-02-28 142 $154.54 4,320 No 4 S Direct
Common Stock Disposition 2024-02-28 111 $155.45 4,209 No 4 S Direct
Common Stock Disposition 2024-02-28 66 $156.38 4,143 No 4 S Direct
Common Stock Disposition 2024-02-28 9 $157.30 4,134 No 4 S Direct
Common Stock Disposition 2024-02-28 1 $158.09 4,133 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2024-02-27 878 $0.00 878 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,754 2026-02-27 No 4 M Direct
Footnotes
  1. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
  2. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $153.94 to $154.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $154.95 to $155.95. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  4. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $155.96 to $156.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  5. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $157.01 to $157.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  6. Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.
  7. The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date.
  8. On February 27, 2023, the reporting person was granted 2,632 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2024, the first tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4.